Botulinum Toxin Evaluated in Digital Ischemia
Individual-level meta-analysis examines response, dosing, and safety across ischemic etiologies
-
By
-
Kathryn Wighton
-
April 3, 2026
-
Clinical Scorecard: Botulinum Toxin Evaluated in Digital Ischemia
At a Glance
| Category | Detail |
|---|
| Condition | Digital ischemia, ischemic digital ulcers, gangrene |
| Key Mechanisms | Botulinum toxin injections improve blood flow and tissue recovery |
| Target Population | Patients with digital ischemia, particularly those with autoimmune conditions |
| Care Setting | Outpatient or clinical settings where botulinum toxin can be administered |
Key Highlights
- 93% complete response in acute digital ischemia
- 90% complete response in ischemic ulcers
- 88% complete response in gangrene
- Most patients required a single injection session
- Adverse events were uncommon, primarily transient muscle weakness and injection site pain
Guideline-Based Recommendations
Diagnosis
- Evaluate for underlying conditions such as systemic sclerosis and other rheumatic diseases
Management
- Administer botulinum toxin injections to interdigital neurovascular bundles at doses of 5 to 10 units per digit side
Monitoring & Follow-up
- Assess for response to treatment and monitor for adverse events
Risks
- Transient muscle weakness (8%) and injection site pain (6%)
Patient & Prescribing Data
Primarily female patients with a mean age of 49 years, often with systemic sclerosis
Higher doses of botulinum toxin are associated with higher complete response rates
Clinical Best Practices
- Consider botulinum toxin for patients unresponsive to vasodilators
- Monitor response rates in autoimmune-related ischemia
- Utilize multiple formulations of botulinum toxin as needed
References
